文献速递妇科肿瘤

局部晚期宫颈癌腹腔镜下腹膜后淋巴结切除术的适应证与手术范围

[The indication and surgery scope for laparoscopic extraperitoneal lymphadenectomy in locally advanced cervical cancer].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2019-01-01

研究纳入81例初治局部晚期宫颈癌患者行腹腔镜下腹膜后淋巴结切除术,评估CT淋巴结最短径(MAD)与血清鳞状细胞癌抗原(SCC-Ag)预测腹膜后淋巴结转移的价值。SCC-Ag≥4.8 ng/ml联合MAD≥1.0 cm预测淋巴结转移的准确率78.3%、特异度100%、约登指数0.6,均显著高于其他单独或联合阈值组(均P<0.05)。作者结论认为MAD≥1.0 cm且SCC-Ag≥4.8 ng/ml及存在髂总/腹主动脉旁淋巴结转移高危因素者可行相应淋巴结切除,而MAD<1.0 cm且SCC-Ag<4.8 ng/ml者淋巴结转移率低,可直接行同步放化疗。

要点

  • 81例患者淋巴结转移率59.3%(48/81),髂总/腹主动脉旁淋巴结转移率24.7%(20/81)。
  • SCC-Ag≥4.8 ng/ml联合MAD≥1.0 cm预测淋巴结转移的准确率78.3%、特异度100%、约登指数0.6。
  • SCC-Ag≥4.8 ng/ml联合MAD≥1.0 cm组21例均出现淋巴结转移,其中38.1%(8/21)为髂总/腹主动脉旁转移。

核心结论

  • CT淋巴结MAD≥1.0 cm且SCC-Ag≥4.8 ng/ml以及存在CILN和(或)PALN转移高危因素者,可行髂总以下肿大淋巴结切除取样以及CILN和PALN切除,以明确淋巴结转移状况并为后续治疗提供准确指导。
  • CT淋巴结MAD<1.0 cm且SCC-Ag<4.8 ng/ml者淋巴结转移率低,可直接行同步放化疗。

研究设计与样本

  • 选择初治的局部晚期宫颈癌患者行腹腔镜下腹膜后淋巴结切除术,分析术前CT影像资料和血清SCC-Ag水平。
  • 比较CT淋巴结MAD≥0.5 cm、MAD≥1.0 cm和SCC-Ag水平预测腹膜后淋巴结转移的价值,并分析CILN和(或)PALN转移的高危因素。
  • 共81例患者行腹腔镜下腹膜后淋巴结切除术。

主要发现

  • 81例患者淋巴结转移率为59.3%(48/81),CILN和(或)PALN转移率为24.7%(20/81),其中仅7例CT示CILN和(或)PALN短径≥0.5 cm。
  • SCC-Ag≥4.8 ng/ml联合MAD≥1.0 cm组21例术后均出现淋巴结转移,转移率100%(21/21),其中38.1%(8/21)出现CILN和(或)PALN转移。
  • SCC-Ag<4.8 ng/ml联合MAD<1.0 cm组17例术后仅4例出现髂总以下盆腔淋巴结(PLN)转移,转移率24.0%(4/17),两组淋巴结转移率差异有统计学意义(P<0.001)。
  • 病理类型、CT示MAD≥1.0 cm的PLN淋巴结数目、CT示至少1个PLN MAD≥1.0 cm和(或)CILN和(或)PALN MAD为0.5~1.0 cm均与CILN和(或)PALN转移有关(均P<0.05)。

关键数值与推荐

  • SCC-Ag判断淋巴结转移的临界值为4.8 ng/ml。
  • SCC-Ag≥4.8 ng/ml联合MAD≥1.0 cm组预测淋巴结转移的准确率78.3%、特异度100%、约登指数0.6。
  • MAD≥0.5 cm组准确率57.9%、特异度12.1%、约登指数0.1;MAD≥1.0 cm组分别为71.1%、75.8%和0.4;SCC-Ag≥4.8 ng/ml组分别为65.0%、57.7%和0.3;SCC-Ag≥4.8 ng/ml联合MAD≥0.5 cm组分别为68.3%、65.4%和0.4;联合MAD≥1.0 cm组与上述各组比较差异均有统计学意义(均P<0.05)。

临床怎么用

  • 作者认为,CT淋巴结MAD≥1.0 cm且SCC-Ag≥4.8 ng/ml以及存在CILN和(或)PALN转移高危因素者,可行髂总以下肿大淋巴结切除取样以及CILN和PALN切除,以明确淋巴结转移状况并为后续治疗提供准确指导。
  • 作者认为,CT淋巴结MAD<1.0 cm且SCC-Ag<4.8 ng/ml者淋巴结转移率低,可直接行同步放化疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the indication and surgery scope for laparoscopic extraperitoneal lymphadenectomy in locally advanced cervical cancer. Methods: Laparoscopic extraperitoneal lymphadenectomy was initially performed on patients with locally advanced cervical cancer. The results of preoperative computed tomography (CT) images and serum level of squamous cell carcinoma antigen (SCC-Ag) were analyzed, and the diagnostic efficiencies of the minimum axial diameter (MAD) of lymph node on CT≥0.5 cm, ≥1.0 cm, serum level of SCC-Ag alone or combined to predict the extraperitoneal lymph node metastases were compared. The high-risk factors of common iliac lymph node (CILN) and para-aortic lymph node (PALN) metastases were also analyzed. Results: The lymph node metastasis rate of 81 patients who received the laparoscopic extraperitoneal lymphadenectomy was 59.3% (48/81). The CILN and/or PALN metastasis rate was 24.7%(20/81), and among them, the MAD of CILN and/or PALN ≥0.5 cm on CT images were in only 7 patients. The threshold of SCC-Ag for evaluating lymph node metastasis was 4.8 ng/ml. The accuracy, specificity and Youden index of SCC-Ag≥4.8+ MAD≥1.0 cm group for predicting lymph node metastasis were 78.3%, 100% and 0.6, respectively, and were significantly higher than 57.9%, 12.1% and 0.1 of MAD≥0.5 cm group, 71.1%, 75.8% and 0.4 of MAD≥1.0 cm group, 65.0%, 57.7% and 0.3 of SCC-Ag≥4.8 ng/ml group and 68.3%, 65.4% and 0.4 of SCC-Ag≥4.8 ng/ml+ MAD≥0.5 cm group (P<0.05). All of the 21 patients in SCC-Ag≥4.8 ng/ml+ MAD≥1.0 cm group were detected to occur lymph node metastases, and the metastasis rate of CILN and/or PALN was 38.1%. While only 4 cases of 17 patients in SCC-Ag<4.8 ng/ml+ MAD<1 cm group were confirmed to occur CILN metastases. The difference of lymph node metastasis rate between these two groups was statistically significant (P<0.001). The pathological type, the number of PLN with MAD≥1.0 cm, at least one of the PLN MAD≥1.0 cm and/or MAD of CILN and/or PALN was 0.5~1.0 cm were associated with the CILN and/or PALN metastases (all P<0.05). Conclusions: Those patients with MAD≥1.0 cm+ SCC-Ag≥4.8 ng/ml and with high-risk factors of CILN and/or PALN metastases should undergo laparoscopic extraperitoneal lymphadenectomy to provide explicit guidance for the subsequent therapy. However, the incidence of lymph node metastasis of patients with SCC-Ag<4.8 ng/ml combined with MAD<1.0 cm is low, therefore these patients can accept concurrent chemoradiotherapy directly. 目的: 探讨局部晚期宫颈癌腹腔镜下腹膜后淋巴结切除的适应证和手术范围。 方法: 选择初治的局部晚期宫颈癌患者行腹腔镜下腹膜后淋巴结切除术,分析患者术前CT影像资料和血清鳞状细胞癌抗原(SCC-Ag)水平,比较CT淋巴结最短径(MAD)≥0.5 cm、MAD≥1.0 cm和SCC-Ag水平预测腹膜后淋巴结转移的价值,分析髂总淋巴结(CILN)和(或)腹主动脉旁淋巴结(PALN)转移的高危因素。 结果: 81例患者行腹腔镜下腹膜后淋巴结切除术,淋巴结转移率为59.3%(48/81);CILN和(或)PALN转移率为24.7%(20/81),其中仅7例CT示CILN和(或)PALN短径≥0.5 cm。SCC-Ag水平判断淋巴结转移的临界值为4.8 ng/ml,SCC-Ag≥4.8 ng/ml+CT淋巴结MAD≥1.0 cm判断淋巴结转移的准确率、特异度和约登指数分别为78.3%、100%和0.6,与CT淋巴结MAD≥0.5 cm组(分别为57.9%、12.1%和0.1)、MAD≥1.0 cm组(分别为71.1%、75.8%和0.4)、SCC-Ag≥4.8 ng/ml组(分别为65.0%、57.7%和0.3)和SCC-Ag≥4.8 ng/ml+CT淋巴结MAD≥0.5 cm组(分别为68.3%、65.4%和0.4)比较,差异均有统计学意义(均P<0.05)。SCC-Ag≥4.8 ng/ml+CT淋巴结MAD≥1.0 cm组21例,术后均出现淋巴结转移,淋巴结转移率为100%(21/21),其中38.1%(8/21)出现CILN和(或)PALN转移;而SCC-Ag<4.8 ng/ml+CT淋巴结MAD<1.0 cm组17例,术后仅4例出现髂总以下盆腔淋巴结(PLN)转移,淋巴结转移率为24.0%(4/17),两组患者的淋巴结转移率差异有统计学意义(P<0.001)。病理类型、CT示MAD≥1.0 cm PLN淋巴结数目、CT示1个PLN MAD≥1.0 cm±MAD 0.5~1.0 cm CILN和(或)PALN均与CILN和(或)PALN转移有关(均P<0.05)。 结论: CT淋巴结MAD≥1.0 cm且SCC-Ag≥4.8 ng/ml以及存在CILN和(或)PALN转移高危因素者,可行髂总以下肿大淋巴结切除取样以及CILN和PALN切除,以明确淋巴结转移状况,为后续治疗提供准确指导。CT淋巴结MAD<1.0 cm且SCC-Ag<4.8 ng/ml者,淋巴结转移率低,可直接行同步放化疗。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhong ML, Liang MR, Jiang W, et al. [The indication and surgery scope for laparoscopic extraperitoneal lymphadenectomy in locally advanced cervical cancer]. Zhonghua Zhong Liu Za Zhi. 2019. PMID: 31014057. doi:10.3760/cma.j.issn.0253-3766.2019.04.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。